Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Clofarabine
Clofarabine with Busulfan · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Clofarabine with Busulfan | EXPERIMENTAL | Clofarabine 40 mg/m2 IV QD × 5 days Busulfan (Busulfex™) 3.2 mg/kg IV QD × 2 days |
| Name | Type | Description |
|---|---|---|
| Clofarabine with Busulfan | DRUG | Clofarabine 40 mg/m2 IV QD × 5 days Busulfan (Busulfex™) 3.2 mg/kg IV QD × 2 days |
Inclusion Criteria: Disease Criteria: * Acute myelogenous leukemia (AML) * Acute lymphocytic leukemia (ALL) * Myelodysplastic syndromes (MDS) Refractory anemia (RA) with adverse cytogenetics (SWOG criteria) or beyond (RAEB, RAEB-T, AML) * Other Myeloproliferative Disorders Myelofibrosis, Agnogenic...
Top 20 of 63 competitors
CLOFARABINE is an investigational small molecule being studied for use in oncology, including B-Cell Lymphoma, Myelodysplastic Syndromes, Solid Tumors, Hematologic Malignancies, Acute Myeloid Leukemia, and Acute Lymphoblastic Leukemia, including in pediatric patients.
CLOFARABINE is being developed by Sanofi, a company listed on the stock exchange under the ticker SNY.
CLOFARABINE is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. It is being studied in clinical trials for various oncological conditions.
CLOFARABINE has been studied in several clinical trials, including NCT00042354, a Phase 2 study in pediatric acute myelogenous leukemia; NCT00315705, a Phase 1 combination study in children with acute leukemias; NCT00477542, a Phase 1 trial in hematologic malignancies; and NCT01196013, a Phase 1 study in Japanese pediatric patients with acute lymphoblastic leukemia.
CLOFARABINE is a distinct drug asset. It is not known to be the same as any other drug under a different name.
CLOFARABINE is a small molecule. Its specific molecular target has not been disclosed in the available information.